Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma : Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules

09/30/2021 | 08:17am EST

Maple Grove, Minn. - Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of three additional strengths of Isotretinoin Capsules. The company now offers Isotretinoin Capsules in 10 mg, 20 mg, 30 mg and 40 mg strengths. Upsher-Smith's product is AB2-rated to the branded product, Absorica (isotretinoin) capsules. This development program is part of a multi-year, multi-product collaboration between Upsher-Smith and New Zealand-based, Douglas Pharmaceuticals Ltd. (Douglas). Douglas, a leading producer of isotretinoin around the globe, will manufacture the product for Upsher-Smith.

As part of its commercialization strategy, Upsher-Smith will distribute the four strengths of Isotretinoin Capsules under its own label and has also entered into a Private Label Supply and Distribution Agreement with Mayne Pharma Inc. (Mayne Pharma). Mayne Pharma is a specialty pharmaceutical company with an established sales and marketing team spanning various therapeutic areas. Based on the agreement, Mayne Pharma will serve as Upsher-Smith's private label distribution partner in the U.S. for Isotretinoin Capsules manufactured under the Upsher-Smith abbreviated new drug application. The isotretinoin capsule market had U.S. sales of approximately $157 million for the 12 months ending July 2021 according to IQVIA.

'The launch of Isotretinoin Capsules marks an important milestone as we continue to grow and diversify our product portfolio,' said Rusty Field, President and CEO, Upsher-Smith. 'This product is among others that we've developed through our collaboration with Douglas. In addition, our supply and distribution agreement with Mayne Pharma has the potential to significantly impact this market given the company's established network of healthcare professionals and vast experience in this market.'

Jeff Douglas, Managing Director of Douglas added, 'This is an exciting time for both Douglas and Upsher-Smith, two companies that are committed to delivering quality, high-value pharmaceutical products. The combination of our development and manufacturing expertise in a variety of therapeutic areas and Upsher-Smith's experience in the U.S. commercializing generics and branded generics makes the launch of this product particularly meaningful. We look forward to our continued partnership.'

'Implementing strategic partnerships and bringing specialty brands and generic products to the U.S. market are fundamental to our company's continued growth,' added Scott Richards, CEO, Mayne Pharma. 'We are pleased to partner with Upsher-Smith and look forward to leveraging our established commercial capabilities to expand patient access to Isotretinoin Capsules.'

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings generics and brands to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.

About Douglas Pharmaceuticals

Douglas specialises in producing prescription drugs for various therapy areas including oncology, dermatology, the central nervous system, and immunology. Douglas also focuses on drug repurposing for global markets, seeking to address serious unmet medical needs using medicines approved by the FDA for other indications. Alongside this, Douglas develops specialty generic products with a preference for those where there is technical, clinical, or IP complexity. The Group's core manufacturing competencies include tablets, soft gelatine capsules, hard shell capsules, powders, liquids and creams, and packaging solutions in an FDA & TGA-certified GMP manufacturing facility. For more information, visit www.douglas.co.nz.

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

Upsher-Smith Laboratories, LLC6701 Evenstad DriveMaple Grove, Minnesota 55369USAGet Directions


Phone: 1-800-654-2299

E: uslinfo@upsher-smith.com

(C) 2021 Electronic News Publishing, source ENP Newswire

12/06MAYNE PHARMA : Change of Director's Interest Notice
12/03MAYNE PHARMA : Notification regarding unquoted securities - MYX
11/30Mayne pharma and mithra announce tga approval of nextstellis oral contraceptive
11/30MAYNE PHARMA : Notification of cessation of securities - MYX
11/29Mayne Pharma Secures Australian Regulatory Approval for Oral Contraceptive
11/28MAYNE PHARMA : 29/11/2021áTGA approval of novel oral contraceptive NEXTSTELLIS
11/28Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods A..
11/22MAYNE PHARMA : 23/11/2021 2021 AGM Chairman's Address
11/22MAYNE PHARMA : 23/11/2021 2021 AGM CEO's Speech
11/22MAYNE PHARMA : 2021 Mayne Pharma AGM Speeches
More news
Sales 2022 461 M 330 M 330 M
Net income 2022 -26,7 M -19,1 M -19,1 M
Net Debt 2022 260 M 186 M 186 M
P/E ratio 2022 -14,0x
Yield 2022 -
Capitalization 477 M 342 M 341 M
EV / Sales 2022 1,60x
EV / Sales 2023 1,33x
Nbr of Employees 967
Free-Float 77,2%
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,27 AUD
Average target price 0,48 AUD
Spread / Average Target 78,0%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Frank C. Condella Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development